Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
47,000
Eli Lilly and Co News & Analysis
stocks
Does the AI trade still have room to run?
Where Morningstar analysts see opportunities—and where they don’t.
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,236.90 | 6.40 | -0.07% |
| CAC 40 | 8,068.93 | 2.25 | 0.03% |
| DAX 40 | 24,293.24 | 529.55 | -2.13% |
| Dow JONES (US) | 48,891.23 | 124.37 | -0.25% |
| FTSE 100 | 10,170.70 | 16.27 | 0.16% |
| HKSE | 27,968.09 | 141.18 | 0.51% |
| NASDAQ | 23,372.03 | 485.41 | -2.03% |
| Nikkei 225 | 53,375.60 | 16.89 | 0.03% |
| NZX 50 Index | 13,348.61 | 64.26 | -0.48% |
| S&P 500 | 6,905.61 | 72.42 | -1.04% |
| S&P/ASX 200 | 8,927.50 | 4.30 | 0.05% |
| SSE Composite Index | 4,157.98 | 6.75 | 0.16% |